Type

Range

Units

Status

Start Date

End Date

Financing

Brief description/objective

An Open-Label Multicenter Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting

The primary objective is to assess the effect of adalimumab on Quality of Life (QOL) as measured by the Short Inflammatory Bowel Disease Questionnaire (SIBDQ), the utilization of health care resources and the costs of care for the UC subjects treated with adalimumab.
The secondary objectives are to assess the effect of adalimumab on UC subjects' additional QOL measurements and disease activities, as well as to further characterize the safety profile of adalimumab.